Low Prognostic Value of Novel Nocturnal Metrics in Patients With OSA and High Cardiovascular Event Risk: Post Hoc Analyses of the SAVE Study.
Cardiovascular Diseases
/ epidemiology
Correlation of Data
Female
Heart Failure
/ blood
Heart Rate
Humans
Hypoxia
/ complications
Male
Middle Aged
Myocardial Infarction
/ blood
Outcome Assessment, Health Care
Oximetry
/ methods
Polysomnography
/ methods
Predictive Value of Tests
Prognosis
Risk Assessment
/ methods
Sleep Apnea, Obstructive
/ complications
SAVE
cardiovascular risk
heart failure
hypoxemia
sleep apnea
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
16
10
2019
revised:
05
06
2020
accepted:
10
06
2020
pubmed:
18
7
2020
medline:
27
5
2021
entrez:
18
7
2020
Statut:
ppublish
Résumé
Traditional methods for the quantification of OSA severity may not encapsulate potential relationships between hypoxemia in OSA and cardiovascular risk. Do novel nocturnal oxygen saturation (Spo We conducted post hoc analyses of the Sleep Apnea Cardiovascular Endpoints (SAVE) trial. In 2687 individuals, Cox proportional hazards models that were stratified for treatment allocation were used to determine the associations between clinical characteristics, pulse oximetry-derived metrics that were designed to quantify sustained and episodic features of hypoxemia, and cardiovascular outcomes. Metrics included oxygen desaturation index, time <90% Spo Neither apnea-hypopnea index, oxygen desaturation index, nor any of the novel Spo Apnea-hypopnea index and oxygen desaturation index were not associated with cardiovascular outcomes. In contrast, the pattern of oxygen desaturation was associated with heart failure and myocardial infarction. However, concomitant risk factors remained the predominant determinants for secondary cardiovascular events and thus deserve the most intensive management.
Sections du résumé
BACKGROUND
Traditional methods for the quantification of OSA severity may not encapsulate potential relationships between hypoxemia in OSA and cardiovascular risk.
RESEARCH QUESTION
Do novel nocturnal oxygen saturation (Spo
STUDY DESIGN AND METHODS
We conducted post hoc analyses of the Sleep Apnea Cardiovascular Endpoints (SAVE) trial. In 2687 individuals, Cox proportional hazards models that were stratified for treatment allocation were used to determine the associations between clinical characteristics, pulse oximetry-derived metrics that were designed to quantify sustained and episodic features of hypoxemia, and cardiovascular outcomes. Metrics included oxygen desaturation index, time <90% Spo
RESULTS
Neither apnea-hypopnea index, oxygen desaturation index, nor any of the novel Spo
INTERPRETATION
Apnea-hypopnea index and oxygen desaturation index were not associated with cardiovascular outcomes. In contrast, the pattern of oxygen desaturation was associated with heart failure and myocardial infarction. However, concomitant risk factors remained the predominant determinants for secondary cardiovascular events and thus deserve the most intensive management.
Identifiants
pubmed: 32679239
pii: S0012-3692(20)31883-3
doi: 10.1016/j.chest.2020.06.072
pmc: PMC8173772
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2621-2631Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL135818
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
J Clin Sleep Med. 2017 May 15;13(5):665-666
pubmed: 28416048
Eur J Heart Fail. 2017 Oct;19(10):1230-1241
pubmed: 28627045
Clin Res Cardiol. 2015 Sep;104(9):705-18
pubmed: 25903111
Int J Cardiol. 2018 Dec 1;272:155-161
pubmed: 30057161
Lancet. 2005 Mar 19-25;365(9464):1046-53
pubmed: 15781100
Int J Stroke. 2016 Jan;11(1):148-50
pubmed: 26763030
Eur Respir J. 2013 Jun;41(6):1340-6
pubmed: 23018907
Respiration. 2009;78(3):278-84
pubmed: 19218786
Circ Res. 2018 Jun 8;122(12):1741-1764
pubmed: 29880501
Circulation. 2017 Nov 7;136(19):1840-1850
pubmed: 29109195
Eur Heart J. 2016 Jun 1;37(21):1695-703
pubmed: 26612581
Sleep. 2015 Aug 01;38(8):1247-57
pubmed: 25669180
J Am Coll Cardiol. 2017 Feb 21;69(7):841-858
pubmed: 28209226
JAMA Cardiol. 2018 Jun 1;3(6):532-540
pubmed: 29541763
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):376-81
pubmed: 8756809
Am J Respir Crit Care Med. 2008 May 15;177(10):1150-5
pubmed: 18276938
Am J Respir Crit Care Med. 2019 Aug 15;200(4):493-506
pubmed: 30764637
Sleep Breath. 2018 Sep;22(3):703-711
pubmed: 29327119
J Clin Hypertens (Greenwich). 2018 Mar;20(3):575-581
pubmed: 29338120
Int J Cardiol. 2018 Nov 15;271:281-288
pubmed: 30049491
JAMA. 2017 Jul 11;318(2):156-166
pubmed: 28697252
Sleep Med. 2010 Feb;11(2):137-42
pubmed: 20064744
Eur Heart J. 2020 Jan 21;41(4):533-541
pubmed: 30590586
Eur Heart J. 2016 Jun 1;37(21):1704-6
pubmed: 26746635
N Engl J Med. 2016 Sep 8;375(10):919-31
pubmed: 27571048
J Thorac Dis. 2010 Sep;2(3):138-43
pubmed: 22263035
Int J Cardiol. 2016 Jan 15;203:1022-8
pubmed: 26630630
Ann Am Thorac Soc. 2017 Dec;14(12):1786-1795
pubmed: 28613935
Eur Heart J. 2019 Apr 7;40(14):1149-1157
pubmed: 30376054
Am J Respir Crit Care Med. 2019 Apr 1;199(7):903-912
pubmed: 30336691
Sleep. 2016 Mar 01;39(3):531-40
pubmed: 26943468
J Am Heart Assoc. 2016 Jul 27;5(8):
pubmed: 27464791